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Abstract
Recent evidence suggests Alzheimer-Disease (AD) to be driven by aggregated Aß. Capital-
izing on the mechanism of molecular mimicry and applying several selection layers, we
screened peptide libraries for moieties inducing antibodies selectively reacting with Aß-
aggregates. The technology identified a pool of peptide candidates; two, AFFITOPES AD01
and AD02, were assessed as vaccination antigens and compared to Aβ1-6, the targeted
epitope. When conjugated to Keyhole Limpet Hemocyanin (KLH) and adjuvanted with alu-
minum, all three peptides induced Aß-targeting antibodies (Abs). In contrast to Aß1-6,
AD01- or AD02-induced Abs were characterized by selectivity for aggregated forms of Aß
and absence of reactivity with related molecules such as Amyloid Precursor Protein (APP)/
secreted APP-alpha (sAPPa). Administration of AFFITOPE-vaccines to APP-transgenic
mice was found to reduce their cerebral amyloid burden, the associated neuropathological
alterations and to improve their cognitive functions. Thus, the AFFITOME-technology deliv-
ers vaccines capable of inducing a distinct Ab response. Their features may be beneficial to
AD-patients, a hypothesis currently tested within a phase-II-study.
Introduction
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder currently affecting
28 million people worldwide [1]. It typically presents with a characteristic amnestic dysfunc-
tion associated with other cognitive-, behavioral- and neuropsychiatric changes impairing a
given individual’s (social) function and ultimately resulting in its death [2]. Available treat-
ments include three acethylcholinesterase inhibitors (AChEI) and one N-Methyl-D-aspartate
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(NMDA) antagonist. Their effects are small and only symptomatic in nature [3]. Thus, there is
a high medical need for a disease-modifying drug.
Accumulation of Amyloid Beta (Ab) appears to be an early event and central to the disease
process. Ab is a proteolytic fragment of the amyloid precursor protein (APP) [4, 5, 6]. APP-
cleavage results in several peptides including Ab1-40 and Ab1-42, which are subject to further
processing. Recent studies suggest Ab-variants and aggregates drive the disease process [7, 8].
Immunotherapy offers the possibility to specifically address Ab-variants and aggregates.
However, targeting self-proteins by immunological means bears the risk of autoimmunity [9].
This is exemplified by autoimmune reactions following the administration of cancer vaccines
[10]. While regarded as immune privileged, the brain is not excluded from such reactions but
represents a relevant target organ as experienced with AN1792 [11] or deduced from the exis-
tence of paraneoplastic autoimmune Central Nervous System (CNS) syndromes [12].
With regard to pathological autoimmunity, both cellular- and humoral effector mechanisms
need to be considered. Avoidance of T-cell responses against CNS-targets is crucial as demon-
strated by AN1792-triggered cases of meningoencephalitis. All second generation AD-vaccines
in clinical development, are designed to avoid activation of target-specific T-cells by restricting
antigen length to<8 amino acids (aa) or by excluding bona-fide T-cells epitopes (CAD106,
ACC001, UB-311, ACI-24 [13, 14, 15]).
The risk of pathological humoral autoimmunity is primarily related to the antigenic epi-
topes addressed. Efficient control of this risk requires selective targeting of structures exclusive-
ly expressed in disease, so called neo-epitopes. The free N-terminus of native, aggregated Ab is
an excellent example of a neo-epitope. Exclusive reactivity to this structure would preclude an-
tibodies (Abs) induced to cross-react with APP and related molecules such as secreted APP-
alpha (sAPPa).
Conventional Aß-vaccines [13, 14, 15, 16] are conjugates of an N-terminal Aß-fragment and
a carrier. The N-terminus of Aß is accessible in monomers, aggregates and amyloid plaques.
Abs elicited by conventional conjugate-vaccines typically fail to discriminate between the vari-
ous Aß-aggregation states. Given the fact that Aß-monomers possess physiological functions
[17, 18, 19, 20] while aggregates exert neurotoxic and synaptotoxic effects [21, 22, 23, 24], a po-
tential benefit of vaccines may require them to elicit Abs selectively addressing Aß-aggregates.
To generate a vaccine that integrates both, targeting the Aß-N-terminus and selective recog-
nition of Aß-aggregates, we devised a technology based on mechanisms of molecular mimicry.
Peptide libraries were screened for peptides exhibiting both features. This yielded several hits.
Two of them, AD01 and AD02, were characterized in more detail. Both did exhibit the in-
tended specificity, and were found to reduce pathological alterations and to ameliorate behav-
ioral deficits of APP-transgenic Tg2576-mice. Results obtained not only suggested them to be
disease-modifying but to have a safety profile superior to conventional Ab1-6-based vaccines.
Material and Methods
AFFITOPE identification and vaccine formulation
AFFITOPE-peptides were identified by screening of peptide libraries (phage display: New En-
gland BioLabs, USA; randomized synthetic hexa- and hepta-peptide libraries: Mimotopes Pty.,
France or MULTIPIN peptide technology), with monoclonal antibodies (mAbs, AFFiRiS, Aus-
tria) specific for the free N-terminus of Aß1-40/42. Identified peptides (EMC microcollections,
Germany) were conjugated to KLH (Biosyn, Germany) using N-gamma-Maleimidobutyryl-
oxysuccinimide ester (GMBS, Thermo Scientific, USA) and adsorbed to Aluminum-hydroxide
(ALUM, Brenntag, Denmark). 30mg peptide/vaccine-dose containing 0.1% ALUM were ap-
plied to animals.
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Animal experiments
All animal experiments were performed in accordance with the Austrian Animal Experiments
Act (TVG2012) using 8–12 week old female C57Bl/6 mice (Charles River, Germany), or
Tg2576-mice (Taconic Farms, USA; 129S6/SvEvTac). Experiments were performed under ap-
proval numbers: LF1-TVG-22/004-2007; M58/007052/2011/7 and LF1-TVG-22/0102011.
General health was checked by modified Smith Kline Beecham, Harwell, Imperial College,
Royal London Hospital, phenotype assessment (SHIRPA) primary observational screen [25].
Mice were injected s.c. 3–6 times in monthly or biweekly intervals. Blood was taken in regular
intervals, plasma prepared and stored until further use. At study end mice were sacrificed, cere-
brospinal fluid (CSF), brains were collected and hemispheres separated. One hemisphere was
fixed in 4% Paraformaldehyde (PFA,Sigma Aldrich, USA), dehydrated and paraffin-embedded.
Brain tissue was sectioned at 7mM using a sliding microtome (Leitz, Germany) and sections
were mounted on Superfrost Plus Slides (Menzel, Germany). The second hemisphere was
quick-frozen at -80°C until further extraction.
Titer determination by ELISA
Standard enzyme-linked immunosorbent assay (ELISA) technology was used to measure levels
of vaccine-induced antibodies in plasma and CSF [26]. Substrates used included murine (Ana-
spec, USA) and human (BACHEM, CH) Aß1-40/42 (each at 5mg/ml), KLH (1mg/ml), recombi-
nant sAPPa (1mg/ml, Sigma-Aldrich, USA), peptide-Bovine serum albumin (BSA) conjugates
(1mM), or Aß-aggregates (5mg/ml, immobilized via Streptavidin). Optical density (OD) was
measured at 405nm using a micro-well reader (Tecan, CH). ODmax/2 was calculated. For de-
termination of antibody selectivity for different Aß species (monomers,oligomers and fibrils),
relative units were calculated as the ratio of OD values for individual measurements: e.g.
OD405nm of Oligomer-specific ELISA signals and OD405nm of Monomer-specific ELISA sig-
nals. Abs 3A5 (AFFiRiS, Austria), mAbP2-1 (Life-Technologies, USA) and 6E10 (Covance,
USA) served as positive controls.
Preparation and characterisation of Aβ-monomers,-oligomers and—fibrils Preparation
of Ab-mono and oligomers (<100kd) was performed according to Johansson et al. with slight
modifications [27]. Pure C-terminally biotinylated Aß1-42 was used to prepare seedless Aß-
monomers. A 1/10 mix of biotinylated and unmodified Aß1-42 (Anaspec, USA) was used for
oligomer- and fibril-production. For preparation of Ab-mono and oligomers Ab was first re-
solved in Hexafluoro-2-propanol (HFIP) over night and subsequently removed by vacuum
centrifugation. Aß peptides were then resuspended and separated using a Superdex 75-10/300
column (GE Healthcare, UK). Elution of monomers and oligomers was determined by detec-
tion at 214nm with oligomers eluting at 8 ml and monomers at 14,5 ml, respectively. Column
calibration was done according to manufacturers protocol (LMWGel Filtration Calibration
Kit; GE Healthcare, UK). For fibril preparation Aß peptides were resuspended in 1xPBS and fi-
brils were assembled by constant rotation of peptide solutions for 24h at 350rpm (37°C). Fi-
bril-preparations were then centrifuged and the pellet was resuspended in elution buffer used
for gelfiltration. Aggregation of Aß-species was confirmed by Thioflavin-T, Western- and Dot
blot analysis (see Appendix).
APP-FACS analysis
To test for APP-specific antibodies a Fluorescence-activated cell sorting (FACS) assay based on
Chinese hamster ovary (CHO)-cells stably expressing a fusion protein of human APP and en-
hanced green fluorescent protein (eGFP) (APP-751-EGFP in pCMV-Sport 6, APP:
NP_958816, pCMV-Sport 6 eGFP-FLAG-tagged (Gift from J.M.Peters, IMP, Austria)) was
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used. A mixture of transfected and un-transfected CHO-cells (50% each) was exposed to dilut-
ed plasma and analysed for double positive cells (eGFP and APP) with a FACScan (BD Biosci-
ences, USA). mAbP2-1 served as positive control. For each sample 10,000 events were acquired
and analysed using CellQuest software (BD Biosciences).
Behavioral tests
To analyse cognitive dysfunction immunised Tg2576 animals were subjected to Modified Mor-
ris water maze task (MWM, with changes) [28] and contextual fear conditioning (CFC, with
changes) [29], both analyzed using AnyMaze software (Stoelting Co, USA). MWMwas subdi-
vided into cued-, hidden task, and probe-trial. Animals were trained in a tap-water filled 110-
cm pool, allowed to swim for 60s with platform occupancy for 10s prior to the next trial. 24h
after the hidden training, memory retention was determined in a single 60s probe-trial without
a platform. The percent of distance swam and time spent in each quadrant was determined.
For CFC, on day 1 mice were placed in the conditioning chamber (AFFiRiS), allowed to habitu-
ate for 2 min. and received three 0.8mA foot-shocks in 2 min intervals plus 30s rest. To assess
contextual learning on day 2, animals were readmitted to the chamber and monitored for 5
min. with s120-240 chosen as time frame for analysis (time freezing = lack of movement except
for respiration). The first two minutes of day 1 were considered as baseline-freezing which was
subtracted from day 2 values. Cognitive testing was initiated 4 weeks prior to sacrification with
4 weeks required to complete both cognitive tests for the individual animals including habitua-
tion phases at the site of testing.
Immunohistochemistry (IHC), immunofluorescence (IF) and analysis of
cerebral Aß
IHC/IF analysis was done as described previously [26]. Reactivity of vaccine-induced antibod-
ies to Aß and APP was determined using an adapted Tissue Amyloid Plaque Immunoreactivity
(TAPIR) analysis [30] on untreated Tg2576- and human AD-brain sections (n = 4, obtained
from Novagen, USA (n = 1) or the UCSD ADRC Brain Bank (n = 3); patients analysed were n
= 3 female and n = 1 male; females: Braak stage VI and male patient Braak stage V) using plas-
ma samples and an APP-specific mAb (22C11, EMDMillipore, USA) as control. Competition
experiments of AD01- and AD02 induced antibodies were performed using specific AFFI-
TOPE-peptides at a final concentration of 10mM. Control antibody used for amyloid staining
on human brain sections was the monoclonal antibody BAM10 (Sigma, USA). For murine sec-
tions monoclonal antibody 6E10 (Signet, USA) was used as control antibody.
For Aß-specific IF-staining, brain sections of immunized Tg2576 were processed for analy-
sis of amyloid load and incidence of amyloid bearing vessels using mAb 3A5 (AFFiRiS AG,
Austria) [26]. All secondary reagents used were obtained from Vector Labs (USA). For TAPIR
analysis, color reactions were performed using DAB-substrate Kit. For IF, sections were
mounted and counterstained using DAPI-containing VECTASHIELD-HardSet Mounting Me-
dium. Sections were examined using MIRAX-SCAN (Carl Zeiss AG, Germany). AD-like pa-
thology in animals was assessed by determining the total tissue area of coronal cross sections of
the total brain as well as the 3A5 positive area on the respective brain sections were determined
and the relative cerebral area occupied by amyloid deposits was calculated using a semi-auto-
mated area recognition program (eDefiniens Architect XD; www.definiens.com). For analysis
three slides/animal and five individual sections/slide were assessed. Sections carrying tissue
artifacts or aberrant staining were excluded. To assess the number of Aß-positive vessels, 3A5
stained sections (n = 3 slides/animal covering cortex and hippocampus and up to five individu-
al sections per slide) have been analysed. Aß-positive vessels were manually counted in sub-
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regions of the cortex as well as in the hippocampus. Number of positive vessels per mm² was
determined.
Analysis of micro-hemorrhaging
To assess the number of micro-hemorrhages, sections were stained using the Iron Stain Kit
(Sigma Aldrich, USA) according to manufacturer’s protocol. 3 slides/animal covering cortex
and hippocampus and up to five individual sections per slide have been analysed. Prussian
blue-positive spots were manually counted in sub-regions of the cortex as well as in the hippo-
campus. Number of positive spots per animal was determined.
Analysis of cerebral levels of Aß by ELISA
The frozen brain hemispheres were thawed and homogenized in homogenisation buffer
(50mMHEPES (pH 7,3), 5mM EDTA, with proteinase inhibitor cocktail: Complete Mini,
Roche, CH) and centrifugated at 4°C for 30 minutes at 40.000 rpm. The supernatant was ali-
quoted and stored at -80°C as soluble fraction. The pellet was re-homogenized in Guanidine-
HCl buffer (5M Guanidine-HCl, 50mMHEPES (pH 7,3), 5mM EDTA with proteinase inhibi-
tor cocktail: Complete Mini, Roche, CH) and centrifuged at 1600g. The supernatant was dia-
lysed against PBS, aliquoted and stored at -80°C as insoluble fraction. Fractions were analysed
for protein content using the Quick Start Bradford Protein Assay according to manufacturer’s
protocol (BioRad, USA).
For quantification of Ab40 and Aß42 peptides in soluble and insoluble fractions, an ELISA
analysis was used (Human Amyloid Beta 40 and Human Amyloid Beta 42 ELISA kits, EMD-
Milipore, USA), The concentration of amyloid peptides in ng/mg of total protein was calculat-
ed for Aß40 and Aß42 in both fractions (soluble and insoluble).
ELISPOT analysis
Animals (C57Bl/6 mice) were immunized three times in biweekly intervals with AD01-
conjugate (30mg net peptide content/mouse/immunization), AD02-conjugate (30mg net pep-
tide content/mouse/immunization) or Ovalbumin (100mg/mouse/immunisation), adjuvanted
with CpG/polyR as adjuvant for T-cell stimulation (CpG (ODN1668: 50 TCC ATG ACG TTC
CTG ATG CT 30, Invivogen, San Diego, USA) 32 mg/mouse; polyR 100 mg/mouse; Sigma-
Aldrich). 1 week after the final immunization animals were sacrificed, splenocytes isolated and
analysed for the presence of target specific T-cells by ELISPOT analysis. ELISPOT analysis was
performed using Ready-SET-Go kits obtained from eBioscience (San Diego, USA) according to
the manufacturer´s protocol. Full length Aß1-42 (50mg/ml,), carrier (KLH, 50mg/ml) or short
MHC-I or MHC-II restricted Ovalbumin-derived peptides Ova 244 (TEWTSSNVMEERKIKV;
MHC class II restricted; 10mg/ml) and Ova 245 (SIINFEKL; MHC class I restricted; 10mg/ml)
as positive control for T-cell induction were used for splenocyte restimulation. Stimulated cells
were assayed for the secretion of either Interleukin 4 (IL4) or Interferon gamma (IFNg). The
stimulation was controlled by application of two positive control stimulators, for IL4 secretion,
Phorbol-12-Myristate-13-Acetate (PMA, working conc.: 20nM) and ionomycin (working
conc.:750nM) and for IFNg secretion Concanavalin A (ConA); working conc.:10 mg/ml;) were
used, respectively.
Statistical analysis
All experiments were done blind-coded. To determine statistical significance, values were com-
pared using (i) one-way analysis of variance for unpaired samples with Tukey’s Multiple
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Comparison Tests, (ii) unpaired T-tests with Welch correction or (iii) Kruskal-Wallis-H-Test
with Dunn’s Multiple Comparison Tests. For correlation analysis a Spearman-Rank-Correlation
has been calculated.
Results
To generate an Aß-vaccine not activating Aß-specific T-cells but inducing Abs selectively
recognizing aggregated Aß and at the same time being specific for the Aß-N-terminus, we
screened peptide libraries with Abs applying various selection filters. Specifically, mAbs di-
rected against the N-terminus of intact, full length Aß1-40/42; (aa1-6: DAEFHR) were used
to screen 109 peptides from different hexa- and hepta-peptide libraries for 6–7 mer peptides
for binding. Specificity of peptide hits was assessed by competition with Aß1-6 (DAEFRH).
Several rounds of selection yielded 68 candidates fulfilling both of the above criteria. Compar-
ing the sequence of the n = 68 peptides to the one of native Aß revealed no candidate with
only 1aa exchange and a difference of n = 2aa in 16%, n = 3aa in 31%, n = 4aa in 23.5% or
n = 5aa in 9%. The remaining 20.5% of the peptides differed at all positions. As a next step,
out of the 68 candidates, 17 were randomly picked and tested for their ability to elicit antibod-
ies reacting to the peptides used for immunization (=immunizing peptide) and, at the same
time, Aß. To this end, they were coupled to KLH, which served as carrier, adsorbed to alumi-
num (ALUM), the adjuvant used, and subcutaneously injected into C57BL/6 and Tg2576-
mice. While all 17 induced Ig-Abs reactive with the respective peptide, only 14 elicited
Abs recognizing Aß1-10 coupled to BSA. Those conjugates were used to mimick binding to
Aß-aggregates, as peptide-BSA conjugates should show a local enrichment of Aß-N-termini
probably similar to the situation present in full length, native Aß-aggregates. Two examples,
AD01 and AD02, characterized by a difference of 50% in their amino acid sequence compared
to the targeted Aß epitope, were characterized in more detail and compared to Aß1-6-KLH-
vaccine.
Immunogenicity of AD-AFFITOPEs
To test the immunogenicity of AD01 and AD02 in comparison to Aß1-6, Tg2576-mice were
injected 6x, s.c., at 4-week intervals with either conjugate-vaccine containing 30mg net peptide.
Vaccination induced Abs were measured in plasma samples at defined time points after immu-
nization (AD01 (n = 9), AD02 (n = 8) and Aß1-6 conjugate (n = 9)). All 3 elicited strong and
comparable IgG titers towards the peptide used for immunization (Fig 1A). Both AFFITOPEs,
AD01 and AD02, elicited Abs to the N-terminus of human Aß at levels comparable to the
Aß1-6-KLH conjugate-vaccine (Fig 1B). Of note, the IgG responses triggered by the 3 conju-
gate-vaccines followed the same kinetics (Fig. 1C). Titers reached a plateau after 2 immuniza-
tions, which was stable during the treatment period. Analyzing the CSF of AD02-immunized
Tg2576-mice demonstrated the presence of peptide-/Aß-specific Abs at a level of 0.1–0.7%
(0.31% +/- 0.05%) of the respective plasma levels (Fig. 1D).
Specificity of the AFFITOPE induced antibody response
We next assessed the specificity of the Abs induced in more detail. Neither AD01-, AD02- nor
Aß1-6-induced plasma samples reacted with irrelevant control peptides such as Aß11-20 of-
fered as BSA conjugates (ELISA, not shown). The reactivity of AD01- and AD02-induced Abs
towards murine Aß was limited and comparable, whereas the signal obtained with Aß1-6-
induced sera was 4 times higher (Fig. 1E). Interestingly, while AD01-elicited plasma samples
reacted strongly with AD01 offered as BSA conjugate in an ELISA setting they barely did so
with AD02-BSA; the opposite was true for AD02-induced samples (approx. 13-fold difference,
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see Fig. 1F). This lacking reactivity towards the respectively other AFFITOPE while retaining
reactivity towards the Aß-N-terminus is most probably explained by the fact that the amino
acid sequences of the two AFFITOPEs tested in this experiment differ from each other by 67%
(n = 4/6aa) but show a similar difference to the native Aß sequence of 50% (n = 3/6aa).
Figure 1. Analysis of the immune response following injection of AD01, AD02 and Aß1-6 conjugate vaccines.Mice were s.c. injected 6 times at a 4-
week interval with AD01 (n = 9), AD02 (n = 8) and Aß1-6 conjugate (n = 9) adsorbed to aluminum hydroxide (ALUM). Plasma was taken in monthly intervals
and at sacrification. Samples were analyzed for their concentration of IgG Abs against specific peptides. Values depicted are the titer calculated as ODmax/2
(at 405nm) plus SEM unless otherwise stated. A) IgG response torwards the respective immunizing peptide (AD01: anti AD01; AD02: anti AD02, Aβ1-6: anti
Aβ1-6); B) Reactivity towards human Aβ1-10 after immunization with AD01-, AD02- and Aβ1-6-based conjugate vaccines. Note, none of the 3 vaccines
elicits Abs that would react with the Aβ11-19, used as a specificity control (not shown); C) Kinetics of the IgG responses to the immunizing peptide following
vaccination with AD01-, AD02- or Aβ1-6 conjugates (AD01. . . black circle, AD02. . . black quadrat, Aß1-6. . . black triangle); D) Ratio of AD02-induced
peptide-specific IgG in CSF and plasma. Analysis of AD02-specific IgG levels in CSF and plasma in 13 AD02-immunized animals revealed an average ratio
of 0.31% (+/- 0.05%). E) Analysis of sera from vaccinated animals regarding their reactivity towards murine Aβ1-42. Only Aβ1-6 immunized animals show a
relevant cross-reactivity to murine Aβ1-42 (Aβ1-6 (n = 9) vs. AD01 (n = 10); p<0.05 and Aβ1-6 (n = 9) vs. AD02 (n = 28); p<0.01); F) IgG response towards
the respective immunizing peptide (AD01: anti AD01; AD02: anti AD02) compared to the respective other AFFITOPE peptide (AD01: anti AD02; AD02: anti
AD01). Animals included: n = 9 for AD01, n = 8 for AD02.
doi:10.1371/journal.pone.0115237.g001
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Exclusion of APP reactivity
Abs used to identify the AD01/AD02 AFFITOPE-family were characterized by recognition of
the Ab-N-terminus and a lack of reactivity with full length APP, the precursor of Ab. To check
whether, as intended, AD01- and AD02-induced Abs would mirror this characteristic of the
paternal mAbs, plasma of AFFITOPE-vaccinated animals were analyzed for APP-binding em-
ploying a FACS assay based on CHO-cells expressing human APP on their surface. Plasma
of immunized animals were analyzed in comparison to APP-specific mAbP2-1, which showed
a dose dependent signal (Fig. 2A-C). Of note, such a signal was not seen in plasma from
AD01 (n = 8) or AD02 immunized animals (n = 30; representative example in Fig. 2E and
data not shown). By contrast, a substantial portion of plasma from Ab1-6-immunized animals,
n = 6/30, was found to contain APP-specific Abs (Fig. 2F).
In addition, plasma samples were also tested for Abs directed against sAPPa, an important
mediator of APP-function. None of the AFFITOPE samples tested (n = 20; Fig. 2G) contained
sAPPa specific Abs detectable by ELISA. This differentiated them from Aß1-6-based vaccines,
which induced sAPPa-reactive Abs in all animals tested (n = 10/10; Fig. 2G). Interestingly, this
APP cross-reactivity was not directly correlated with the absolute anti-Aß titer in these samples
(Spearman-Rank-Correlation r = 0.4316, p = 0.2129; Fig. 2H), implying that this reactivity
against cleaved forms of APP is a unique feature of a fraction of Abs present within the oligo-
clonal response elicited by Aß1-6-based vaccines.
As a third method to assess the potential cross reactivity of AD01- and AD02-induced anti-
bodies to human APP/sAPPa and an APP-eGFP fusion protein, a Western blot analysis was
performed (see Appendix, S2A Fig.). In this assay, both AD01- and AD02 induced plasma sam-
ples failed to detect full length human APP/sAPPa in brain extracts from 12 month old Tg2576
animals or in cell extracts from CHO cells stably expressing a fusion protein of human APP
and eGFP (also used in the FACS based analysis mentioned above). As expected the APP spe-
cific positive control antibody 22C11 was able to detect APP/sAPPa and APP-eGFP using this
method.
Differential reactivity towards Aß-aggregation states
To characterize AD01- and AD02-induced plasma samples with regard to their reactivity to-
wards defined Ab-aggregation states we devised ELISA systems covering monomers, oligo-
mers and fibrils. 6E10, known to bind Ab in all its aggregation states (Fig 3), was used as
standard. Of note, the patterns of reactivity seen with AD01, AD02 and Ab1-6 were found to
differ substantially. Ab1-6-induced antibodies behaved like 6E10 reacting equally well with all
Ab-aggregation states tested (Fig. 3). By contrast, AFFITOPE-elicited Abs exhibited a differ-
ential recognition pattern of the various Ab-aggregation states. AD01-induced plasma reacted
with aggregated (both oligomers and fibrils) but not with monomeric Ab. AD02-induced sera
were found to recognize fibrillar Ab only (Fig. 3) and showed only limited reactivity towards
oligomeric Aß preparations and no reactivity with monomeric Ab using ELISA based
analyses.
In a second set of experiments, Aß aggregate specificity of AD01 and AD02 induced anti-
bodies was analysed employing peptide ELISAs with aggregated Aß both as bait coated on the
ELISA plate and as peptide used as competitor for antibody binding to the immobilized Aß ag-
gregates (see Appendix, S2C Fig.). Indeed this competition experiment revealed a concentra-
tion dependent, specific reduction of the binding to aggregates and hence further substantiates
the claim of selective aggregate recognition by AFFITOPE induced antibodies.
In addition, AD01 and AD02 induced antibodies were also tested for binding to monomeric,
dimeric and aggregated Aß by Western blot analyses. As suggested by ELISA results (see
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Fig. 3), AD02 induced antibodies showed a lack of reactivity to monomeric and dimeric Aß
and against low molecular weight (MW) Aß aggregates (<100kD). Reactivity could only be de-
tected to high MW aggregates (>100kd, see Appendix, S2B Fig.). In contrast to ELISA based
results, AD01 induced antibodies displayed reactivity to monomeric and dimeric Aß probably
due to different sensitivity of the assays used. In line with previous results (see Fig. 3 and
Figure 2. AFFITOPE induced Antibodies spare APP and sAPPa.Mice were s.c. injected 3 times at a 2-week interval with AD01-, AD02- or Aß1-6-conjugate
vaccines adjuvanted with ALUM. Plasma was taken at sacrification. A-D depict controls for full length APP-specific FACS analysis using the APP-specific mAb
mP2-1 (A-C) or naïve plasma (D); E and F show two exemplaric analyses of AD02 and Aß1-6 induced plasma in this assay. G and H depict analysis of immune
responses against sAPPa following vaccination (n = 10 animals/treatment group) by peptide ELISA. For analysis of the presence of APP specific antibodies, the
% of cells shifting in the non-APP expressing population and the% of cells shifting in the presence of the secondary antibody only were subtracted from the% of
APP-positive cells shifting as indicator of APP binding. The assay threshold was set to 5%. Positive controls (A-C) show an Ab dose dependent (LOD of1ng/ml
mAb) shift of the APP positive but not of the APP-negative population. No reactivity was seen with plasma from naïve animals (D). AD02-induced samples show
no reactivity to the APP-positive as well as APP-negative populations (E) whereas Aß1-6 induced sera show a specific shift at a dilution of 1/200 in the APP-
positive cell population (upper right quadrant) with only very limited reactivity to the non-APP expressing cell population (lower and upper left quadrant; F).
Neither AD01 nor AD02 was found to elicit sAPPa-specific Abs (G). On the contrary, following Aß1-6 immunization, sera of all 10 animals were shown to cross-
react with sAPPa (G). A correlation analysis for anti Aß1-42 and anti sAPPa reactivity of plasma samples from animals undergoing Aß1-6 immunization (H) fails
to detect a significant correlation indicating a highly individual response against sAPPa (Pearson r = 0.1534; R²= 0.02354); Titers determined were calculated
based onODmax/2 values. aAPP. . .anti APP specific Ab, neg.contr. . . is secondary Ab only; AD01, AD02 is AD01- and AD02-vaccine induced plasma, Aß1-6 is
Aß1-6 vaccine induced plasma, sec.only. . . secondary Ab only, pos. control. . .. mAb P2-1
doi:10.1371/journal.pone.0115237.g002
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Appendix, S2B Fig.) they also reacted against all aggregated Aß forms present on Western blots
similar to the non-confomer specific control antibody 4G8 (see Appendix; S2B Fig.).
Furthermore, we assessed the reactivity of AD01- and AD02-induced plasma on brain tissue
of Tg2576-mice and of AD-patients (n = 4) applying a standard DAB immuno-histochemical
protocol [26] and using 22C11 as comparator reacting with full length APP. AD01- or AD02-
elicited plasma were found to exclusively stain amyloid deposits and to spare neuronal surfaces
with a comparable staining pattern as the Aß specific control antibody 6E10 in brain sections
of Tg2576-mice (Fig. 4 A, B, D, E, J and K). In addition, a loss of immunoreactivity could be de-
tected when AD01- or AD02-elicited plasma was pre-adsorbed with the respective AFFITOPE-
peptides to inhibit antibody binding to amyloid plaques, indicating specificity of the AFFI-
TOPE-induced antibody staining observed in these animals (Fig. 4G, H). Immunohistochemi-
cal analysis of APP reactivity showed an opposite staining pattern with specific reactivity on
neuronal cell walls and plaque-surrounding neuritic alterations both in the hippocampus and
the cortex of Tg2576 mice (Fig. 4M and data not shown)
A comparable staining pattern was seen on human AD-brain sections. The analysis of
human sections of n = 4 patients revealed a specific amyloid deposit staining of AD01-(Fig. 4F)
Figure 3. AFFITOPE induced antibodies differ in their reactivity towards aggregated forms of Aβ. A)
Reactivity of Aβ1-6-, AD01- and AD02-induced Abs towards Aβ in various aggregation states. Bars represent
the means of OD values (at 405nm) of individual plasma samples (duplicates) derived from single animals
immunized with Aß1-6, AD01 or AD02;. B) Relative units of values frommonomeric- and either oligomeric- or
fibrillar Aß detection by plasma samples from Aß1-6- or AFFITOPE-treated animals are depicted (mean
+/-SEM, n = 5 samples/vaccine). Levels around one indicate a similar OD whereas values above one indicate
a predominant binding to either oligomers or fibrils as compared to monomeric Aß1-42. Reactivity of sera was
tested against seedless monomeric, oligomeric and fibrillar Aß1-42, respectively. Purity of the preparations
was comparable and exceeded 90%. The monoclonal Ab 6E10 (Signet) was used as positive control.
doi:10.1371/journal.pone.0115237.g003
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and AD02-induced Abs (Fig. 4I) present in murine plasma similar to staining obtained by
using control antibody BAM10 (Fig. 4C). No staining was detectable with plasma derived from
a naïve, untreated animal (Fig. 4L). These findings corroborated the Aß-specificity described
above characterized by the lack of APP cross-reactivity (Fig. 2).
Figure 4. AFFITOPE-induced antibodies detect amyloid deposits but spare neuronal APP onmurine and human brain sections. Sections prepared
from the hippocampus (A, D, G, J, K, M) and the cortex (B, E, H), of a 12 month old Tg2576 mouse were incubated with plasma of AD01- (D, J) or AD02-
treated mice (E, K) and, for control purposes, with the antibodies 6E10 (A+B) and mAb 22C11 (J, K, M), recognizing Aß and full length APP. G) and H) show
a loss of immunoreactivity on Tg2576 brain sections incubated with AD01- and AD02-induced samples which were mixed with the respective AFFITOPE
peptide to inhibit AFFITOPE specific staining (i.e. G: AD01-induced plasma + 10µMAD01 peptide, H: AD02-induced plasma + 10µMAD02 peptide).
Sections prepared from the cortex of a female AD patient (C, F, I, L Braak stage VI,) were incubated with the Aß specific control antibody BAM10 (C), AD01-
(F) and AD02-induced plasma (I) or plasma from naïve control mice as negative control (L). Binding of the Abs was detected using a standard DAB immuno-
histochemistry protocol. The analysis of human sections reveals a specific amyloid deposit staining of AD01-(F) and AD02-induced Abs (I) present in murine
plasma similar to staining obtained by using control antibody BAM10 (C), whereas no staining was detectable with plasma derived from a naïve, untreated
animal (L). Pictures were taken at a magnification of 20x. Scale bars: 200µm; circles in G and H indicate amyloid deposits devoid of amyloid specific staining
by AD01- or AD02- induced antibodies following peptide-specific competition.
doi:10.1371/journal.pone.0115237.g004
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AFFITOPE vaccination does not activate Aβ-specific T-cells
AD01 and AD02 are 7 amino acids long (6 containing the mimicry information +1 residue
used for conjugation). Therefore, these AFFITOPE peptides should be too short to bind to
MHCmolecules and activate peptide specific T-cells. In addition, their amino acid sequences
differ from the one of the N-terminus of Ab. To formally test whether conjugate vaccines con-
taining AFFITOPEs AD01 and AD02 would activate AFFITOPE-peptide or Ab-specific T-
cells, splenocytes of immunized, non-transgenic animals were analyzed by ELISPOT. To this
end, groups of n = 6 C56BL/6 mice were immunized 3 times at 2 week-intervals with AD01-
KLH, AD02-KLH or ovalbumin (OVA). One week after the last immunization, splenocytes
were isolated and stimulated in vitro with the carrier (KLH), Ab or ovalbumin-derived MHC
class I- (IFNg assay) and MHC class II (IL-4 assay) binding peptides. Cultures were assessed
for IL-4- and IFNg-producing cells, which, given the stimulation conditions, reflect T-
lymphocytes that had been primed during vaccination. Assay controls included stimulation
with PMA/ionomycin (IL-4 assay) and concanavalin A (IFNg assay) and confirmed cell viabili-
ty/functionality (Fig. 5A and B). Restimulation with the carrier protein demonstrated that both
AFFITOPE vaccines had led to the induction of a KLH-specific T-cell response. Such a re-
sponse was not evident in OVA-immunized animals. However, in vitro stimulation of spleno-
cytes derived from AD01 and AD02-immunized animals with either AD01- or AD02-peptides
as well as with recombinant Ab did not yield a signal over background confirming the expected
inability of the two AFFITOPEs of activating either AFFITOPE peptide- as well as Ab-specific
T-cells. This view is supported by experimental evidence from transgenic animals undergoing
active immunotherapy using AD01 and AD02: To test whether AD01 and AD02 immunother-
apy would lead to brain infiltration of T-cells, brain sections of n = 20 AD02-immunized-,
n = 9 AD01-immunized-, and n = 10 carrier-treated Tg2576 mice were subjected to immuno-
histochemical examination using CD3 specific antibodies to detect potential CD3+ T cells
(see Appendix, S3 Fig.). Despite that fact that in most of the AD01- and AD02- treated animals
immunisation had resulted in a reduction of amyloid deposition (see Fig. 6 and 7), none of the
brains was found to be infiltrated by CD3+ T cells.
Both vaccine candidates lower cerebral Aß without triggering cerebral
amyloid angiopathy (CAA) or micro-hemorrhages (MH)
To test whether AD01 and AD02 would lower cerebral amyloid load, groups of 6-months old
Tg2576-mice (n = 10/group) were vaccinated 6x at monthly intervals with either vaccine (inde-
pendent experiments), and sacrificed at 14 months of age. Their brains were assessed for dif-
fuse and dense-cored plaques by IF-staining using monoclonal antibody 3A5. Cortical as well
as hippocampal sections of KLH/ALUM-injected controls were covered by numerous amyloid
plaques. They covered on average 2.00% (AD01 experiment) and 0.69% (AD02 experiment)
of the area analyzed. By contrast, respective brain areas of AD01- and AD02-immunized
Tg2576-mice contained significantly less deposits (Fig. 6 A-D) covering 0.21% (Fig. 6E) and
0.77% (Fig. 6F), respectively. Thus, AD01 reduced the area covered by amyloid by 62%
(p<0.05) and AD02 by 70% (p<0.05).
In addition to the analysis of amyloid deposition in situ we also assessed the effect of AFFI-
TOPE vaccination on the cerebral level of Aß1-40 and Aß1-42 by peptide ELISA. Therefore,
brain samples of AD01 and AD02 treated Tg2576 animals were extracted and soluble and in-
soluble brain fractions were subjected to Human Aß40 and Human Aß42 ELISA (EMD-
Milipore, USA) analysis. Neither AD01 nor AD02 treated animals showed a significant change
of soluble Aß1-40 and Aß1-42 following immunotherapy (see Fig. 7A and B). In contrast for
both vaccines, insoluble Aß was reduced significantly following immunotherapy (see Fig. 7C
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and D). For AD02 a 60% reduction of Aß1-40 (p<0.05) and a 62% (p = 0.056) reduction of
Aß1-42 could be detected. AD01 showed a reduction of 69% (Aß1-40, p<0.05) and 78% (Aß1-
42, p<0.01), respectively. This differences are most probably reflecting a selective removal of
aggregated and deposited Aß while soluble forms were only reduced to a low amount.
Figure 5. AD01 and AD02 immunization does not induce self-reactive T-Cells. Neither AD01 nor AD02
treated mice showed any sign of Aß-specific T-cell activation in two ELISPOT assays (A+B). Re-stimulation
using the carrier (KLH) was resulting in a stimulation of IL4 and Interferon gamma (INFg) secretion, indicative
of the presence of carrier specific T-cells following immunization with AD01 and AD02. The positive control
Ovalbumin was able to induce a slightly higher Interferon gamma secretion than the carrier used in the
AFFITOPE vaccines (B). A+B depict two representative ELISPOT analyses following vaccination of
Ovalbumin, AD01 and AD02. A) IL4 secretion following splenocyte restimulation using carrier (KLH) and Aß
compared to the controls OVA244 (TEWTSSNVMEERKIKV; MHC class II restricted to demonstrate
Ovalbumin induced T-cells) and PMA/ionomycin (PMA/Ion); B) IFNg secretion following splenocyte
restimulation compared to the positive controls OVA245 (SIINFEKL; MHC class I restricted to demonstrate
Ovalbumin induced T-cells) and Concavalin A (ConA). Bg describes the background of secretion in non-
stimulated cells in this assay. Numbers are the total number of spots per million of cells seeded on the
ELISPOT plates.
doi:10.1371/journal.pone.0115237.g005
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As amyloid removal appears to partially occur via the vasculature and peripheral sink mech-
anisms [31, 32, 33] and can be associated with enhanced micro-bleedings following active and
passive immunotherapy [34], blood-vessels of relevant brain regions (cortex and hippocam-
pus) were analyzed for their amyloid content by 3A5 staining and the same regions were as-
sessed for microbleedings by Prussian Blue staining, respectively. At the time point assessed,
the number of 3A5-positive vessels per mm2 is comparable for control- and AFFITOPE-treated
Figure 6. AFFITOPE immunization reduces cerebral amyloid deposition in Tg2576mice.Groups of
Tg2576 mice (n = 10/group) received 6 monthly injections of KLH/ALUM or AD01-, AD02-conjugate
vaccines. Brains were isolated, 8 weeks after the 6th immunization. Quantification of the relative total brain
area covered by amyloid deposits (in % of total tissue analyzed) is based on immuno-fluorescence staining
using the Aß specific mAb 3A5. Representative subregions of the cortex (A, B) and dentate gyrus (C, D) of
controls (A, C) and AD02- (B, D) immunized mice are shown. E) AD02-vaccination reduces the relative area
covered by amyloid deposits compared to controls by 70% (diffuse and dense cored amyloid; p˂0.05). F)
AD01 vaccination reduces the relative area covered by amyloid deposits compared to controls by 62%
(diffuse and dense cored amyloid; p˂0.05). Box plots in E and F showminimum, 25% percentile, median, 75%
percentile and maximum. Asterisks in E+F indicate statistical significant difference (p<0.05); Arrowhead in C
indicates unspecific fluorescence from a cerebral vessel. Scale bar: 200µM; pictures taken at 10x
magnification
doi:10.1371/journal.pone.0115237.g006
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Figure 7. AFFITOPE immunization reduces cerebral amyloid levels in Tg2576mice (ELISA).Groups of Tg2576 mice (n = 10/group) received 6 monthly
injections of KLH/ALUM or AD01-, AD02-conjugate vaccines. Brains were isolated, 8 weeks after the 6th immunization, extracted and soluble and insoluble
brain fractions were subjected to Human Aß40 and Human Aß42 ELISA (EMD-Milipore, USA) analysis. Neither AD01- (A) nor AD02 treated animals (B)
showed a significant change of soluble Aß1-40 and Aß1-42 following immunotherapy as compared to control immunized animals. Insoluble Aß was reduced
significantly following immunotherapy. C) AD01 treated animals showed a 69% reduction of Aß1-40 levels (p = 0.005) and a 78% reduction of Aß1-42
(p = 0.015), respectively. D) For AD02 a 60% reduction of Aß1-40 (p = 0.033) and a 62% (p = 0.056) reduction of Aß1-42 could be detected. Results are
expressed as average SEM and are given as ng/mg total protein. Black bars represent Aß1-40 and white bars represent Aß1-42 values. Asterisks in C+D
indicate statistical significant difference (*. . .p<0.05, **. . .p<0.01);
doi:10.1371/journal.pone.0115237.g007
Figure 8. Cerebral amyloid angiopathy andmicrohemorrhaging are unchanged following AFFITOPE-immunization. The analysis of the incidence of
amyloid bearing vessel in AFFITOPE- and control treated animals by assessing 3A5 staining in cerebral vessels reveals no significant differences (A-C). A)
Example from a cortical section of a control animal. B) Example from a cortical section of an AD02-treated animal. C) Quantitative analysis demonstrating the
average number of 3A5 positive vessels/mm² (avg. +/- SEM) in control (n = 9), and AD02-treated animals (n = 8). The analysis of the incidence of cerebral
micro-hemorrhages in these animals by assessing Hemosiderin staining (= Prussian Blue) did not show significant differences at 14 months of age (D-F). D)
Example from a cortical section of a control animal. E) Example from a cortical section of an AD02-treated animal. F) quantitative analysis demonstrating the
average number of Hemosiderin positive vessels/animal in control (n = 9), and AD02 treated animals (n = 8, respectively); Arrows indicate 3A5 positive
vessels, arrowheads indicate amyloid deposits. Scale bar: 50µm; pictures taken at 20x magnification
doi:10.1371/journal.pone.0115237.g008
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animals (see Fig. 8) compatible with the view that AFFITOPE vaccines do not enhance
CAA after repeated immunization. Moreover, the MH-number was low and comparable for
both immunized and control mice (Fig. 8) indicating no effect on the occurrence of micro-
hemorrhages following AFFITOPE immunization.
Both vaccine candidates improve functional deficits of APP-transgenic
mice
To evaluate the effect of AFFITOPE-vaccination on cognitive functions, we applied, MWM
(AD01 and AD02) and CFC (AD02 only) analyzing spatial and contextual memory and learn-
ing in Tg2576-mice.
In the MWM learning phase, both AD02- and control-treated mice (receiving KLH/
ALUM) showed a similar learning capability (Fig. 9A). During probe-trials for assessing mem-
ory retention, AD02-treated mice performed significantly better than control mice (Fig. 9B,
p<0.05). No differences in swim speed between the two groups were detectable during the
probe trial (data not shown). Analysing the percentage of mice per group searching in the tar-
get quadrant for>25% of the time, showed that 82% of the AD02-treated animals were able to
correctly remember the former platform position compared to 40% in the control group (data
not shown). A similar MWM-analysis using AD01-treated animals revealed a similar improve-
ment in spatial memory. However, while AD01-immunized animals performed better than
controls, the effect did not reach statistical significance (Fig. 9C, p = 0.1).
Figure 9. AFFITOPE vaccination improves cognitive function of Tg2576-mice. Spatial memory and learning were assessed with MWM (A-C),
contextual learning and memory with CFC (D-E). Cognitive testing was initiated 4 weeks prior to sacrification in groups of AFFITOPE-immunized or Tg2576
control mice. A) Learning curves as assessed by escape latency for visible as well as hidden platform training. Both groups exhibited comparable learning
capacities. B) Spatial memory assessed by probe trial using % of time spent in target quadrant at the end of MWM. AD02 vaccination improves spatial
memory by 40% (p˂0.05). Similar results were obtained for distance travelled (not shown). C) Spatial memory assessed by probe trial using time spent in
target quadrant at the end of MWM. AD01 vaccination increases the time spent in the target quadrant by 25% (n = 5 animals/group; p = 0.1). D) Development
of the time freezing on day 1 and day 2 of the CFC-analysis revealed that AD02-treated animals show slightly lower freezing levels in response to foot shocks
on day 1 (p> 0,05), but froze significantly longer during the retention phase of the CFC test at day 2 (p<0,01). E) % of time freezing at the end of CFC testing.
Parameter depicted in D and E is the % of time the animals are 99% immobile during a representative 2-minute period on day two of the CFC testing
paradigm. *..p<0.05; **..p<0.01.
doi:10.1371/journal.pone.0115237.g009
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CFC demonstrated that AD02-treated mice were superior to control animals (Fig. 9D+E).
Although showing slightly lower freezing levels in response to day 1 foot-shocks (Fig. 9D), ani-
mals froze significantly more on day 2 during the representative 2 min period of the retention
phase of the test (p<0.01, Fig. 9D+E). The significant improvement of AD02-treated animals
was also detectable by averaging the performance in CFC during the whole 5 minutes on day 2
(p<0.05, data not shown). Taken together, these findings demonstrate AFFITOPE-vaccination
to effectively reduce memory defects in Tg2576-mice in two learning paradigms.
Discussion
The work presented aimed at generating novel Aß-targeting AD-vaccines with specific fea-
tures. Specifically, they were designed to (i) trigger Abs specific for the Aß-N-terminus (ii)
being selective for aggregated Aß and (iii) preclude the activation of AFFITOPE peptide- or
Aß-specific T-cells. This was accomplished via the mechanism of molecular mimicry and by
applying sequential selection filters. It led to the identification of two candidates, AD01 and
AD02, which fulfill the predefined criteria and exhibit disease-modifying activity in the models
tested.
Molecular mimicry, in terms of humoral immunity, denotes the phenomenon of Abs not
only recognizing a single epitope but more than one resembling each other and, thus, being in-
distinguishable for the Ab. This is not uncommon. Most examples we are aware of relate to
negative effects. They include autoimmune reactions as a result of bacterial- or viral infections,
neoplasias (e.g., paraneoplastic CNS disorders) or vaccination (e.g., AN1792-triggered cases of
meningoencephalitis) [12, 35, 36]. We explored the possibility of exploiting molecular mimicry
for the development of AD-vaccines with optimized safety- and efficacy features. To this end,
Abs known to bind the Aß-N-terminus (DAEFRH), were exposed to a pool of 109 6- or 7-mer
peptides. In addition to DAEFRH, a total of 68 peptides were found to bind the Abs employed
(frequency of cross-reactive peptides: 4.0x10-8). 20.5% of the hits differed at every aa-position
from the original epitope, the remaining had 2 or more aa-exchanges. For all 68 peptides, bind-
ing could be competed with DAEFRH arguing for their interaction with the antigen binding
sites of the Abs. Out of the 68 peptides, 17 were picked and tested for their ability to elicit Abs
when administered as peptide-KLH conjugates adjuvanted with aluminum. All 17 elicited an
Ab-response to the immunizing peptide, 14 of them induced Abs reacting with Aß1-10-BSA
conjugates, which resemble to some extent Aß-aggregates given the high density of binding
sites on BSA following conjugation. These data confirm and quantify the phenomenon of mo-
lecular mimicry for mAbs primarily known to bind to the Aß-N-terminus. They also demon-
strate, at least for mice, that it is possible to reverse and hence exploit the process. That is,
cross-reacting peptides, foreign to the human proteome, can trigger Abs that recognize the
„original“epitope and have imprinted „additional“features, e.g. selective Aß-aggregate recogni-
tion and selective recognition of peptides derived from the same screen.
Beyond pathophysiology, design of AD-vaccines has to consider physiological functions
and the dynamics of the ensuing Ab-response. While AD-pathophysiology is complex, it ap-
pears that toxicity resides within the aggregated Aß fraction affecting neurons and synapses
[21, 22, 23, 24]. By contrast, monomeric Aß as well as sAPPa and APP possess physiological
functions. Monomeric Aß regulates the proliferation of neural progenitors and contributes to
synaptic function [17, 18, 19, 20, 37]. APP and sAPPa are involved in the development and
plasticity of the nervous system, regulation of neurite outgrowth, neuronal proliferation and
contribute to cognitive performance and memory [38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49,
50]. Abs recognizing physiological elements of the Aß-pathway, such as the ones induced by
Aß1-6-KLH, could have negative effects via various, mutually non-exclusive mechanisms:
Targeting Aggregated Aß by Active Vaccines
PLOS ONE | DOI:10.1371/journal.pone.0115237 January 22, 2015 17 / 22
interference with the above molecules and their functions, Ab-triggered cytotoxicity. Moreover,
APP/sAPPa and serum Aß would sequester such Abs thereby lowering their levels. Of note, the
advantages of Abs with the above specificity may not be discernible in AD-models used, which
are characterized by a strong over-expression of Aß and sAPPa. So far, AFFITOPE-vaccines
are the first second-generation vaccines which report to spare binding to the above molecules.
Other examples either do not provide any analyses on cross-reactivity [14, 15, 16] or report a
lack of APP/sAPP reduction without providing data or an analysis of antibody binding other
than on fixed tissue, therefore probably underestimating potential cross-reactivity in vivo [13].
Beyond differential targeting of Aß-variants, AD01 and AD02 reduced cerebral amyloid
load by 62- and 70%, respectively. This compares favorably to conventional vaccines [13, 14,
15, 16, 51]. In addition to the IF analysis, assessing the amount of insoluble Aß showed a selec-
tive and significant reduction following AD01 and AD02 immunotherapy, whereas soluble
forms of Aß1-40 and Aß1-42 were not significantly changed. This selective removal of insolu-
ble and deposited Aß could further support the selectivity of AFFITOPE-vaccines for Aß-
aggregates.
Amyloid reduction was not associated with an increase in detectable MH or CAA, as seen
with other vaccines [52, 53], but with improvement of cognitive dysfunction as assessed by
MWM and CFC. Furthermore, we could also demonstrate the inability of the two AFFITOPE
vaccines of activating either AFFITOPE peptide- as well as Ab-specific T-cells. This is in line
with similar experimental results obtained using AFFITOPE vaccines targeting alpha Synuclein
(aSyn) in animal models of synucleinopathies [54]. In these experiments, no aSyn AFFITOPE
peptide- or target specific T-cells (i.e. alpha Synuclein) could be detected by ELISPOT- or
immunohistochemical analyses following active immunotherapy in mice using peptide conju-
gate vaccines [54].
In conclusion, data presented support the feasibility of the proposed technology based on
molecular mimicry. Vaccine candidates identified, AFFITOPEs AD01 and AD02, exhibit high
specificity (Aß-aggregates but no monomers) defining their high safety (e.g., sparing of APP/
sAPPa-recognition) and efficacy profiles. Given their disease-modifying potential both have
been introduced to clinical testing in mild to moderate AD with AD02 being currently assessed
in a multicentre phase II study in early AD-patients.
Supporting Information
S1 Fig. Aggregation analysis of Aβ-monomers,-oligomers and—fibrils. To assess aggrega-
tion status of Ab-monomers,-oligomers and—fibrils, ThT Fluorescence analsyis (A) as well as
Dot blot (B) and Western blot (C) were performed. (A) Monomer preparations show relative
fluorescence units (RFU) close to background indicating the absence of fibrillar Aß. Oligomeric
and fibrillar preparations contained ThT positivive aggregates with fibrillar preparations con-
taining significantly more positive aggregates (RFUs>5000) than oligomeric preparations
(RFUs of ca.2000). (B) Dot Blot analysis using NAB 228 showed equal signals for Ab-
monomers,-oligomers and—fibrils whereas analysis using A11 did show only oligomer
specific signals and failed to detect Ab-monomer and—fibril preparations indicating that only
the oligomer preparations were also containing oligomeric species, not detectable in the other
two preparations. (C) Western Blot analysis using NAB 228 showed equal signals for Ab-
monomers and—oligomers. Oligomeric preparations contained Ab‐dimers, ‐trimers and ‐
tetramers as well as oligomers with a size of approx. 35–40kd (weak signal in C) in this analysis.
No fibril specific signals could be detected.
(TIF)
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S2 Fig. Reactivity of AD01- and AD02-induced antibodies to Aß and sAPPa. The reactivity
of AD01- and AD02-induced Abs towards full length APP/sAPPa/APP-eGFP as well as differ-
ent forms of Ab was assessed by Western blot analysis (A+B). Specificity of AFFITOPE-in-
duced antibodies for aggregated Aß was assessed by competition ELISA (C). A) Western blot
analysis using brain extracts form a 12 month old female Tg2576 mouse and from CHO cells
stably expressing a human APP-eGFP fusion protein showed a lack of reactivity of AD01- and
AD02- induced antibodies against full length APP/sAPPa and APP-eGFP fusion protein
whereas the positive control antibody 22C11 (APP-specific) was able to detect APP/sAPPa and
APP-eGFP, respectively. B) Western Blot analysis of aggregated recombinant Aß revealed a
lack of reactivity of AD02-induced Abs against mononmeric and dimeric Aß as well as low mo-
lecular weight (MW) Aß aggregates (<100kD). AD02-induced Abs react predominantly
against high MWAß aggregates (>100kD). AD01 induced antibodies, as the non-confomer
specific antibody 4G8 showed binding to Ab-monomers,—dimers, as well as low and MWAß
aggregates. C) ELISA experiment demonstrating the selectivity of AD01- and AD02- induced
antibodies for aggregated Aß by concentration dependent, specific competition using aggregat-
ed Aß. Bars represent the means of OD values (at 405nm) of individual samples derived from
single animals immunized with AD01 or AD02. Reactivity of sera was tested against aggregated
Aß1-42 immobilised on ELISA plates (1mM). Competition was done using plasma samples (di-
lution of 1/100) and aggregate concentrations of 0.5mg/ml and 1mg/ml, respectively. A:
1. . .Tg2576 brain extract; 2. . .CHO APP-eGFP cell extract; B: m+d. . .Aß monomer and
dimer, l+h. . .low and high MWAß aggregates; C: sec. only. . . secondary antibody used as
background control for the ELISA; grey and black bars indicate OD values for AD01 (grey)
and AD02 (black) induced antibodies (+/- aggregated Aß)
(TIF)
S3 Fig. T-cell response to immunization with AD01 and AD02. Immunostaining of T-cells
present in the perivascular space with an anti-CD3 antibody. No CD3-positive cells were ob-
served in brains of Control (A), AD01 (B) or AD02 (C) immunized animals. CD3 positive cells
could be detected in murine splenic tissue sections used as positive controls for staining (D).
Pictures in A-C show CA1 region of brains from 14 month old Tg2576 animals undergoing im-
munotherapy. Per mouse, a total of20 individual brain sections were assessed. Scale bar = 50
mm, pictures taken at a 20x magnification.
(TIF)
S1 Appendix. Materials And Methods.
(DOCX)
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